Gina Sangha

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Gene regulatory complexes: their role and regulation across normal and malignant hematopoiesis.

Gene regulatory complexes: their role and regulation across normal and malignant hematopoiesis.

Journal: Experimental hematology

Published: April 02, 2025

Frailty and haemophilia; speaking the language of geriatricians.

Frailty and haemophilia; speaking the language of geriatricians.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 27, 2023

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.

Journal: British journal of haematology

Published: December 11, 2022

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.

Journal: Hematology (Amsterdam, Netherlands)

Published: June 06, 2022

Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset.

Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset.

Journal: HemaSphere

Published: March 26, 2022

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.

Journal: Hematology (Amsterdam, Netherlands)

Published: February 08, 2022

Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma.

Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma.

Journal: Therapeutic advances in hematology

Published: November 04, 2021

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.

Journal: PloS one

Published: May 26, 2021

Limited utility of the HScore in detecting secondary haemophagocytic lymphohistiocytosis in COVID-19.

Limited utility of the HScore in detecting secondary haemophagocytic lymphohistiocytosis in COVID-19.

Journal: British journal of haematology

Published: May 16, 2021

Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis.

Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: September 14, 2020

Response.

Response.

Journal: Clinical medicine (London, England)

Published: April 08, 2018

The application game.

The application game.

Journal: Clinical medicine (London, England)

Published: December 03, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026